PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
NCT ID: NCT01070550
Last Updated: 2016-06-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4680 participants
OBSERVATIONAL
2007-06-30
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
NCT01066819
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
NCT01066793
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
NCT01416610
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
NCT01087944
A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6
NCT02791256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
Peginterferon alfa-2a (Pegasys®)
Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peginterferon alfa-2a (Pegasys®)
Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic hepatitis C
* informed consent to data collection
Exclusion Criteria
* previous treatment with peginterferon and/or ribavirin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gratwein, , Austria
Graz, , Austria
Innsbruck, , Austria
Linz, , Austria
Linz, , Austria
Vienna, , Austria
Vienna, , Austria
Vienna, , Austria
Vienna, , Austria
Salvador, Estado de Bahia, Brazil
Goiânia, Goiás, Brazil
Belo Horizonte, Minas Gerais, Brazil
Belém, Pará, Brazil
Recife, Pernambuco, Brazil
Recife, Pernambuco, Brazil
Rio de Janeiro, Rio de Janeiro, Brazil
Rio de Janeiro, Rio de Janeiro, Brazil
Rio de Janeiro, Rio de Janeiro, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
Rio Grande, Rio Grande do Sul, Brazil
Botucatu, São Paulo, Brazil
Campinas, São Paulo, Brazil
Campinas, São Paulo, Brazil
Ribeirão Preto, São Paulo, Brazil
Santos, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
São Paulo, São Paulo, Brazil
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Kelowna, British Columbia, Canada
Nanaimo, British Columbia, Canada
New Westminster, British Columbia, Canada
Prince George, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Winnipeg, Manitoba, Canada
St. John's, Newfoundland and Labrador, Canada
Barrie, Ontario, Canada
Brampton, Ontario, Canada
Etobicoke, Ontario, Canada
Greater Sudbury, Ontario, Canada
Guelph, Ontario, Canada
London, Ontario, Canada
Newmarket, Ontario, Canada
North Bay, Ontario, Canada
Oakville, Ontario, Canada
Oshawa, Ontario, Canada
Oshawa, Ontario, Canada
Ottawa, Ontario, Canada
Scarborough Village, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Windsor, Ontario, Canada
Lévis, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Québec, Quebec, Canada
Québec, Quebec, Canada
Saint-Charles-Borromée, Quebec, Canada
Saint-Jean-sur-Richelieu, Quebec, Canada
Osijek, , Croatia
Pula, , Croatia
Split, , Croatia
Zadar, , Croatia
Zagreb, , Croatia
Agen, , France
Aix-en-Provence, , France
Albi, , France
Amiens, , France
Angers, , France
Annecy, , France
Antibes, , France
Argenteuil, , France
Argenteuil, , France
Aulnay-sous-Bois, , France
Aulnay-sous-Bois, , France
Bastia, , France
Beaumont, , France
Beausoleil, , France
Beauvais, , France
Besançon, , France
Besançon, , France
Béziers, , France
Béziers, , France
Bordeaux, , France
Bordeaux, , France
Boulogne-Billancourt, , France
Bourgoin, , France
Caen, , France
Chambéry, , France
Clermont-Ferrand, , France
Clichy, , France
Colmar, , France
Cornebarrieu, , France
Creil, , France
Créteil, , France
Créteil, , France
Dijon, , France
Dijon, , France
Druex, , France
Évreux, , France
Freyming-Merlebach, , France
Fréjus, , France
Grasse, , France
Grenoble, , France
Hérouville-Saint-Clair, , France
Hyères, , France
La Rochelle, , France
La Valette-du-Var, , France
Lagny-sur-Marne, , France
Le Chesnay, , France
Le Havre, , France
Le Kremlin-Bicêtre, , France
Lille, , France
Limoges, , France
Lomme, , France
Lorient, , France
Lyon, , France
Lyon, , France
Lyon, , France
Marseille, , France
Marseille, , France
Marseille, , France
Marseille, , France
Marseille, , France
Martigues, , France
Meaux, , France
Melun, , France
Menton, , France
Metz, , France
Metz, , France
Monaco, , France
Montauban, , France
Montpellier, , France
Montpellier, , France
Mulhouse, , France
Muret, , France
Nanterre, , France
Nantes, , France
Nantes, , France
Nice, , France
Nice, , France
Nîmes, , France
Nîmes, , France
Ollioules, , France
Orange, , France
Orléans, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Perpignan, , France
Pessac, , France
Périgueux, , France
Poissy, , France
Poitiers, , France
Pont-à-Mousson, , France
Reims, , France
Rennes, , France
Rouen, , France
Saint-Dizier, , France
Saint-Jean-de-Verges, , France
Saint-Laurent-du-Var, , France
Saint-Mandé, , France
Sète, , France
Ste Maxime, , France
Strasbourg, , France
Tarbes, , France
Toulon, , France
Toulouse, , France
Toulouse, , France
Toulouse, , France
Toulouse, , France
Tourcoing, , France
Valenciennes, , France
Vandœuvre-lès-Nancy, , France
Villejuif, , France
Ajka, , Hungary
Békéscsaba, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Debrecen, , Hungary
Eger, , Hungary
Győr, , Hungary
Gyula, , Hungary
Kaposvár, , Hungary
Kecskemét, , Hungary
Kistarcsa, , Hungary
Miskolc, , Hungary
Miskolc, , Hungary
Nyíregyháza, , Hungary
Pécs, , Hungary
Pécs, , Hungary
Szeged, , Hungary
Szekszárd, , Hungary
Székesfehérvár, , Hungary
Szolnok, , Hungary
Szombathely, , Hungary
Tatabánya, , Hungary
Zalaegerszeg, , Hungary
Zalaegerszeg, , Hungary
Chihuahua City, , Mexico
Chihuahua City, , Mexico
Culiacán, , Mexico
Guadalajara, , Mexico
Hermosillo, , Mexico
Mexicali, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Monterrey, , Mexico
Puebla City, , Mexico
Puebla City, , Mexico
Casablanca, , Morocco
Casablanca, , Morocco
Rabat, , Morocco
Skopje, , North Macedonia
Bydgoszcz, , Poland
Lodz, , Poland
Warsaw, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Arad, , Romania
Brasov, , Romania
Brasov, , Romania
Brasov, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Cluj-Napoca, , Romania
Cluj-Napoca, , Romania
Constanța, , Romania
Constanța, , Romania
Constanța, , Romania
Iași, , Romania
Iași, , Romania
Sector 2, , Romania
Târgu Mureş, , Romania
Timișoara, , Romania
Timișoara, , Romania
Belgrade, , Serbia
Niš, , Serbia
Novi Sad, , Serbia
Celje, , Slovenia
Ljubljana, , Slovenia
Maribor, , Slovenia
Novo Mesto, , Slovenia
Eskilstuna, , Sweden
Halmstad, , Sweden
Huddinge, , Sweden
Linköping, , Sweden
Lund, , Sweden
Örebro, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ascione A, Bruno S, Coppola C, Mangia A, Orlandini A, Schmitz M, Deodato B, Puoti M. Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort. Hepatogastroenterology. 2014 Jun;61(132):1094-106.
Ferenci P, Aires R, Ancuta I, Arohnson A, Cheinquer H, Delic D, Gschwantler M, Larrey D, Tallarico L, Schmitz M, Tatsch F, Ouzan D. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin. Liver Int. 2014 Nov;34(10):1550-9. doi: 10.1111/liv.12439. Epub 2014 Jan 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MV21012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.